Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.52
+0.22 (1.27%)
At close: May 12, 2025, 4:00 PM
17.52
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Apellis Pharmaceuticals stock have an average target of 39.06, with a low estimate of 18 and a high estimate of 80. The average target predicts an increase of 122.95% from the current stock price of 17.52.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 | 5 | 4 |
| Buy | 4 | 4 | 4 | 4 | 5 | 6 |
| Hold | 8 | 8 | 8 | 8 | 8 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 18 | 18 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy → Buy Downgrades $75 → $52 | Strong Buy → Buy | Downgrades | $75 → $52 | +196.80% | May 9, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Hold Downgrades $41 → $23 | Strong Buy → Hold | Downgrades | $41 → $23 | +31.28% | May 9, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $21 → $18 | Hold | Maintains | $21 → $18 | +2.74% | May 8, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $28 → $20 | Hold | Maintains | $28 → $20 | +14.16% | May 8, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $30 → $26 | Hold | Maintains | $30 → $26 | +48.40% | May 8, 2025 |
Financial Forecast
Revenue This Year
877.07M
from 781.37M
Increased by 12.25%
Revenue Next Year
1.06B
from 877.07M
Increased by 21.08%
EPS This Year
-1.03
from -1.60
EPS Next Year
0.23
from -1.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 984.9M | 1.3B | 1.5B | ||
| Avg | 877.1M | 1.1B | 1.3B | ||
| Low | 764.3M | 848.4M | 1.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.0% | 44.3% | 45.7% | ||
| Avg | 12.2% | 21.1% | 17.8% | ||
| Low | -2.2% | -3.3% | -3.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.19 | 1.92 | 3.81 | ||
| Avg | -1.03 | 0.23 | 1.48 | ||
| Low | -1.95 | -1.16 | 0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,540.7% | ||
| Avg | - | - | 537.7% | ||
| Low | - | - | 174.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.